X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs CIPLA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD CIPLA LUPIN LTD/
CIPLA
 
P/E (TTM) x 28.2 40.0 70.7% View Chart
P/BV x 3.0 3.7 80.3% View Chart
Dividend Yield % 0.6 0.5 122.0%  

Financials

 LUPIN LTD   CIPLA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
CIPLA
Mar-18
LUPIN LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,465663 221.0%   
Low Rs727479 151.8%   
Sales per share (Unadj.) Rs349.6189.0 184.9%  
Earnings per share (Unadj.) Rs5.617.6 31.6%  
Cash flow per share (Unadj.) Rs29.634.0 86.9%  
Dividends per share (Unadj.) Rs5.003.00 166.7%  
Dividend yield (eoy) %0.50.5 86.8%  
Book value per share (Unadj.) Rs300.3176.7 169.9%  
Shares outstanding (eoy) m452.08805.12 56.2%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x3.13.0 103.8%   
Avg P/E ratio x197.232.5 607.7%  
P/CF ratio (eoy) x37.116.8 220.8%  
Price / Book Value ratio x3.63.2 113.0%  
Dividend payout %90.017.1 527.6%   
Avg Mkt Cap Rs m495,502459,724 107.8%   
No. of employees `00017.023.6 72.2%   
Total wages/salary Rs m28,64726,901 106.5%   
Avg. sales/employee Rs Th9,273.66,446.1 143.9%   
Avg. wages/employee Rs Th1,681.01,139.4 147.5%   
Avg. net profit/employee Rs Th147.4600.0 24.6%   
INCOME DATA
Net Sales Rs m158,042152,193 103.8%  
Other income Rs m1,5043,577 42.0%   
Total revenues Rs m159,545155,769 102.4%   
Gross profit Rs m31,47528,264 111.4%  
Depreciation Rs m10,85913,228 82.1%   
Interest Rs m2,0441,142 178.9%   
Profit before tax Rs m20,07617,470 114.9%   
Minority Interest Rs m-710-   
Prior Period Items Rs m35-28 -126.6%   
Extraordinary Inc (Exp) Rs m-14,644-775 1,889.0%   
Tax Rs m2,8852,501 115.3%   
Profit after tax Rs m2,51314,166 17.7%  
Gross profit margin %19.918.6 107.2%  
Effective tax rate %14.414.3 100.4%   
Net profit margin %1.69.3 17.1%  
BALANCE SHEET DATA
Current assets Rs m122,095108,141 112.9%   
Current liabilities Rs m50,95638,322 133.0%   
Net working cap to sales %45.045.9 98.1%  
Current ratio x2.42.8 84.9%  
Inventory Days Days8597 87.2%  
Debtors Days Days12074 161.2%  
Net fixed assets Rs m129,876109,411 118.7%   
Share capital Rs m9041,610 56.2%   
"Free" reserves Rs m134,866140,682 95.9%   
Net worth Rs m135,771142,292 95.4%   
Long term debt Rs m64,24536,621 175.4%   
Total assets Rs m263,054228,606 115.1%  
Interest coverage x10.816.3 66.4%   
Debt to equity ratio x0.50.3 183.9%  
Sales to assets ratio x0.60.7 90.2%   
Return on assets %1.76.7 25.9%  
Return on equity %1.910.0 18.6%  
Return on capital %3.710.0 37.4%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14151,691 102.8%   
Fx outflow Rs m19,33521,033 91.9%   
Net fx Rs m33,80730,658 110.3%   
CASH FLOW
From Operations Rs m17,51214,628 119.7%  
From Investments Rs m-14,073-8,540 164.8%  
From Financial Activity Rs m-14,921-3,855 387.1%  
Net Cashflow Rs m-11,4822,431 -472.3%  

Share Holding

Indian Promoters % 46.6 16.0 291.3%  
Foreign collaborators % 0.2 20.8 1.0%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 31.9 23.7 134.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.1 26.2 38.5%  
Shareholders   98,259 161,166 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  ELDER PHARMA  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 21, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - DIVIS LABORATORIES COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS